Transfer of adoptive immunity by intra-arterial injection of tumor-immune pig lymph node cells

Symes, M. O.; Mitchell, J. P.; Eckert, H; Roberts, Julian; Feneley, R. C. L.; Chir, M.; Tribe, C. R.; Biol, Teresa Lai M.I.

doi:10.1016/0090-4295(78)90288-1

Cited by 12 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1978, Symes et al treated 24 patients with recurrent bladder cancer after radiotherapy, with intra-arterial injection of lymph node cells from pigs previously immunized by cancer cells. A remission of the disease was noted in 11/24 patients, and 3/11 remained in remission for one year [42].…”

Section: Immunization Studies Against Tumor Transplants Using Non-tumor Tissuesmentioning

confidence: 93%

Combining the past and present to advance immuno-radiotherapy of cancer

Koukourakis

2021

International Reviews of Immunology

View full text Add to dashboard Cite

Since its first clinical application, 120 years ago, radiotherapy evolved into a major anti-cancer treatment modality, offering high cure rates in many human malignancies. During the past ten years, the establishment of immune checkpoint inhibitors (iCis) in cancer therapeutics has vigorously reintroduced the immune system's role in the outcome of radiotherapy and, conversely, the role of radio-vaccination in the efficacy of immunotherapy. The knowledge and clinical experience that founded the current era of immuno-radiotherapy started alongside with the birth of radiotherapy, and evolved through exhaustive experimental work, clinical trials on active specific immunotherapy, frustrating attempts to validate the importance of cytokine administration with radiotherapy, and, finally, the encouraging iCi-based clinical trials that opened the door to a far more encouraging perspective; radio-vaccination, through its old and new methods, is rising as a research field that promises to cure, previously incurable, disease. in this critical review, we focus on the scientific knowledge gathered through more than a century of research on radiotherapy interactions with the immune system. Understanding the origins of this promising therapeutic approach will substantially contribute to developing new immuno-radiotherapy policies in the fight against cancer.

show abstract

Section: Immunization Studies Against Tumor Transplants Using Non-tumor Tissuesmentioning

confidence: 93%

Combining the past and present to advance immuno-radiotherapy of cancer

Koukourakis

2021

International Reviews of Immunology

View full text Add to dashboard Cite

show abstract

“…The transfer of passive immunity by IA injection of tumor-immune pig lymph node cells has been used to treat bladder cancer in humans. 72 Complete clinical regression of tumor occurred in 83% of the cases treated with phytohemagglutinin compared with 53% of a control group. On histologic examination, 67% of the phytohemagglutinin group of patients showed no signs of tumor compared with 16% of the control group.…”

Section: Lntraarterial Chemotherapy With Irradiation Ormentioning

confidence: 94%

“…The transfer of passive immunity by IA injection of tumor-immune pig lymph node cells has been used to treat bladder cancer in humans. 72 Okuda et al73 treated 24 patients with maxillary sinus carcinoma by topical application of gelatin sponge saturated with phytohemagglutinin combined with IA infusion of 5-FU and concurrent irradiation. Phytohemagglutinin may have immunostimulating properties and has been observed to cause accumulation of immunocytes at the site of infection.…”

Section: Future Developments In Ia Therapymentioning

confidence: 99%

Intraarterial chemotherapy for head and neck cancer, part 2: Clinical experience

Baker

Wheeler

1984

Head Neck

View full text Add to dashboard Cite

Despite almost 3 decades of experience, the use of intraarterial (IA) chemotherapy for the treatment of head and neck cancer is not universally accepted. The overall reported response rates are not substantially different from the therapeutic results obtained with systemic therapy. The additional complications associated with establishing and maintaining arterial access have further dampened enthusiasm for this approach. It is clear that considerable improvement in the techniques and efficacy of IA chemotherapy is necessary. This second and last part of this article considers the past and present clinical experience with IA therapy in the treatment of head and neck cancer and explores future developments.

show abstract

Host Evaluation of Patients with Bladder Cancer

Lachand¹,

Auvert²

1982

Clinical Bladder Cancer

View full text Add to dashboard Cite

Transfer of adoptive immunity by intra-arterial injection of tumor-immune pig lymph node cells

Cited by 12 publications

References 4 publications

Combining the past and present to advance immuno-radiotherapy of cancer

Combining the past and present to advance immuno-radiotherapy of cancer

Intraarterial chemotherapy for head and neck cancer, part 2: Clinical experience

Host Evaluation of Patients with Bladder Cancer

Contact Info

Product

Resources

About